These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1112 related articles for article (PubMed ID: 26343814)

  • 1. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R; Tikkanen I; Cannon CP; Crowe S; Woerle HJ; Broedl UC; Johansen OE
    Diabetes Obes Metab; 2015 Dec; 17(12):1180-93. PubMed ID: 26343814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
    Chilton R; Tikkanen I; Hehnke U; Woerle HJ; Johansen OE
    Diabetes Obes Metab; 2017 Nov; 19(11):1620-1624. PubMed ID: 28387058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
    Tikkanen I; Narko K; Zeller C; Green A; Salsali A; Broedl UC; Woerle HJ;
    Diabetes Care; 2015 Mar; 38(3):420-8. PubMed ID: 25271206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
    Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
    Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
    Jung S; Bosch A; Kannenkeril D; Karg MV; Striepe K; Bramlage P; Ott C; Schmieder RE
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):364-371. PubMed ID: 31816038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
    Tikkanen I; Chilton R; Johansen OE
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):81-6. PubMed ID: 26808705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
    Mancia G; Cannon CP; Tikkanen I; Zeller C; Ley L; Woerle HJ; Broedl UC; Johansen OE
    Hypertension; 2016 Dec; 68(6):1355-1364. PubMed ID: 27977392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
    Ferdinand KC; Izzo JL; Lee J; Meng L; George J; Salsali A; Seman L
    Circulation; 2019 Apr; 139(18):2098-2109. PubMed ID: 30786754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.
    Ferdinand KC; Seman L; Salsali A
    Curr Med Res Opin; 2018 Feb; 34(2):361-367. PubMed ID: 29139301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
    Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
    Kohler S; Zeller C; Iliev H; Kaspers S
    Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
    Lunder M; Janić M; Japelj M; Juretič A; Janež A; Šabovič M
    Cardiovasc Diabetol; 2018 Dec; 17(1):153. PubMed ID: 30509271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
    Cherney DZ; Perkins BA; Soleymanlou N; Har R; Fagan N; Johansen OE; Woerle HJ; von Eynatten M; Broedl UC
    Cardiovasc Diabetol; 2014 Jan; 13():28. PubMed ID: 24475922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
    Papazafiropoulou AK; Mpoumi L; Papantoniou S; Rallatou M; Antonopoulos S; Melidonis A
    Ann Afr Med; 2021; 20(2):154-155. PubMed ID: 34213486
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.